Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

702. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.

Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. 16467234 2006 02 09 2006 02 13 2016 10 17 1538-3598 295 6 2006 Feb 08 JAMA JAMA Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. 655-66 Multiple epidemiologic studies and some trials have linked diet with cardiovascular disease (CVD) prevention, but long-term (...) Rep. 2007 Dec;9(6):431-3 18377781 ACP J Club. 2006 Jul-Aug;145(1):6-7 16813355 JAMA. 2006 Jul 19;296(3):279-80; author reply 280-1 16849658 JAMA. 2006 Jul 19;296(3):280; author reply 280-1 16849659 Curr Diab Rep. 2006 Nov;6(5):387-8 17077000 Evid Based Nurs. 2006 Oct;9(4):112-3 17076013 Aged Cardiovascular Diseases prevention & control Coronary Disease epidemiology mortality prevention & control Diet, Fat-Restricted Energy Intake Fatty Acids administration & dosage Female Follow-Up Studies Humans

JAMA2006

703. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. 17011942 2006 10 02 2006 10 12 2015 06 16 1474-547X 368 9542 2006 Sep 30 Lancet (London, England) Lancet Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. 1155-63 Evidence-based treatment for hypercholesterolaemia in Japan has been hindered by the lack of direct evidence in this population (...) Controlled Trial Research Support, Non-U.S. Gov't England Lancet 2985213R 0140-6736 0 Anticholesteremic Agents KXO2KT9N0G Pravastatin AIM IM Lancet. 2006 Dec 9;368(9552):2052; author reply 2052 17161725 Lancet. 2006 Dec 9;368(9552):2051-2; author reply 2052 17161724 Lancet. 2006 Dec 9;368(9552):2051; author reply 2052 17161723 Curr Atheroscler Rep. 2007 Oct;9(4):257-57 18173949 Lancet. 2006 Sep 30;368(9542):1135-6 17011926 Adult Aged Anticholesteremic Agents therapeutic use Cardiovascular Diseases

Lancet2006

704. Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults.

Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. CONTEXT: While parental cardiovascular disease (CVD) doubles the risk for CVD in offspring, the extent of increased risk associated with sibling CVD is unclear. OBJECTIVE: To determine, using validated events, whether sibling CVD predicts outcome in middle-aged adults independent of other risk factors. DESIGN, SETTING, AND PARTICIPANTS: The Framingham Offspring Study, an inception cohort

JAMA2005

705. Prevalence and cardiovascular disease correlates of low cardiorespiratory fitness in adolescents and adults.

Prevalence and cardiovascular disease correlates of low cardiorespiratory fitness in adolescents and adults. CONTEXT: Population surveys indicate that physical activity levels are low in the United States. One consequence of inactivity, low cardiorespiratory fitness, is an established risk factor for cardiovascular disease (CVD) morbidity and mortality, but the prevalence of cardiorespiratory fitness has not been quantified in representative US population samples. OBJECTIVES: To describe

JAMA2005

706. Combination pharmacotherapy for cardiovascular disease.

Combination pharmacotherapy for cardiovascular disease. Cardiovascular disease (CVD) is the major cause of death in developed countries and is rapidly becoming the major cause of death in the developing world. The increasing rates of obesity and type 2 diabetes, however, may slow the current favorable trends for deaths attributable to CVD in many developed countries. To improve control of risk factors for CVD, Wald and Law proposed a "polypill," containing a statin, a diuretic, a beta (...) -blocker, an angiotensin-converting enzyme inhibitor, aspirin, and folic acid. This combination pharmacotherapy (CP) could be made widely available without treating specific risk factors or individuals. A workshop sponsored by the Centers for Disease Control and Prevention reviewed the concept of CP for both primary and secondary prevention. Combination pharmacotherapy may prove to be efficacious but may also have side effects and poor adherence, which may be greater than or less than that of other preventive

Annals of Internal Medicine2005

707. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study.

Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. OBJECTIVE: To estimate the high risk group for cardiovascular disease in a well defined Norwegian population according to European guidelines and the systematic coronary risk evaluation system. DESIGN: Modelling study. SETTING: Nord-Tröndelag health study 1995-7 (HUNT 2), Norway. PARTICIPANTS: 5548 participants of the Nord-Tröndelag health (...) study 1995-7, aged 40, 50, 55, 60, and 65. MAIN OUTCOME MEASURES: Distribution of risk categories for cardiovascular disease, with emphasis on the high risk group. MAIN RESULTS: At age 40, 22.5% (95% confidence interval 19.3% to 25.7%) of women and 85.9% (83.2% to 88.6%) of men were at high risk of cardiovascular disease. Corresponding numbers at age 50 were 39.5% (35.9% to 43.1%) and 88.7% (86.3% to 91.0%) and at age 65 were 84.0% (80.6% to 87.4%) and 91.6% (88.6% to 94.1%). At age 40, one out

BMJ2005 Full Text: Link to full Text with Trip Pro

708. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.

Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. CONTEXT: Current guidelines for cardiovascular risk detection are controversial with regard to the clinical utility of different lipid measures, non-high-density lipoprotein cholesterol (non-HDL-C), lipid ratios, apolipoproteins, and C-reactive protein (CRP). OBJECTIVE: To directly compare the clinical utility of total cholesterol (...) , low-density lipoprotein cholesterol (LDL-C), HDL-C, non-HDL-C, apolipoproteins A-I and B(100), high-sensitivity CRP, and the ratios of total cholesterol to HDL-C, LDL-C to HDL-C, apolipoprotein B(100) to apolipoprotein A-I, and apolipoprotein B(100) to HDL-C as predictors of future cardiovascular events in women. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study of 15,632 initially healthy US women aged 45 years or older (interquartile range, 48-59 years) who were enrolled between November 1992 and July

JAMA2005

709. A nurse managed smoking cessation and relapse prevention programme did not reduce smoking rates at 12 months beyond rates achieved by usual care in women with cardiovascular disease

A nurse managed smoking cessation and relapse prevention programme did not reduce smoking rates at 12 months beyond rates achieved by usual care in women with cardiovascular disease A nurse managed smoking cessation and relapse prevention programme did not reduce smoking rates at 12 months beyond rates achieved by usual care in women with cardiovascular disease | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via (...) at 12 months beyond rates achieved by usual care in women with cardiovascular disease Article Text Treatment A nurse managed smoking cessation and relapse prevention programme did not reduce smoking rates at 12 months beyond rates achieved by usual care in women with cardiovascular disease Free Wendy Peterson , RN, PhD , Postdoctoral Fellow Statistics from Altmetric.com No Altmetric data available for this article. Sivarajan Froelicher ES, Miller NH, Christopherson DJ, et al . High rates

Evidence-Based Nursing (Requires free registration)2005

710. Waist hip ratio independently predicted death from cardiovascular and coronary heart disease in Australian men and women

Waist hip ratio independently predicted death from cardiovascular and coronary heart disease in Australian men and women Waist hip ratio independently predicted death from cardiovascular and coronary heart disease in Australian men and women | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Waist hip ratio independently predicted death from cardiovascular and coronary heart disease in Australian men and women Article Text Aetiology Waist hip ratio independently predicted death from cardiovascular and coronary heart disease in Australian men and women

Evidence-Based Medicine (Requires free registration)2005

711. Impaired fasting glucose and cardiovascular outcomes in postmenopausal women with coronary artery disease.

Impaired fasting glucose and cardiovascular outcomes in postmenopausal women with coronary artery disease. BACKGROUND: Type 2 diabetes increases risk for cardiovascular disease. Persons with impaired fasting glucose levels may also have increased risk. OBJECTIVE: To evaluate the association between glucose status and cardiovascular outcomes and the effect of lowering the fasting glucose level criterion for impaired fasting glucose from a lower limit of 6.1 mmol/L (110 mg/dL) to 5.6 mmol/L (100 (...) mg/dL). DESIGN: Prospective cohort study. SETTING: 20 U.S. clinical centers. PATIENTS: 2763 postmenopausal women with established coronary heart disease (CHD) who were followed for 6.8 years. MEASUREMENTS: Any CHD event (nonfatal myocardial infarction or CHD death), stroke or transient ischemic attack (TIA), congestive heart failure (CHF) hospitalization, and any cardiovascular event. RESULTS: During follow-up, 583 women had a CHD event, 329 women had a stroke or TIA, and 348 women were

Annals of Internal Medicine2005

712. Oestrogen plus progestogen did not prevent cardiovascular disease in postmenopausal women

Oestrogen plus progestogen did not prevent cardiovascular disease in postmenopausal women Oestrogen plus progestogen did not prevent cardiovascular disease in postmenopausal women | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oestrogen plus progestogen did not prevent cardiovascular disease in postmenopausal women Article Text Treatment Oestrogen plus progestogen did not prevent cardiovascular disease in postmenopausal women Free Irene Travale , RN, MSN(c) Statistics from Altmetric.com No Altmetric data

Evidence-Based Nursing (Requires free registration)2005

713. Secular trends in cardiovascular disease risk factors according to body mass index in US adults.

Secular trends in cardiovascular disease risk factors according to body mass index in US adults. CONTEXT: Prevalence of obesity in the United States has increased dramatically in recent decades, but the magnitude of change in cardiovascular disease (CVD) risk factors among the growing proportion of overweight and obese Americans remains unknown. OBJECTIVE: To examine 40-year trends in CVD risk factors by body mass index (BMI) groups among US adults aged 20 to 74 years. DESIGN, SETTING

JAMA2005

714. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors.

Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. CONTEXT: Elderly persons with chronic kidney disease have substantial risk for cardiovascular mortality, but the relative importance of traditional and novel risk factors is unknown. OBJECTIVE: To compare traditional and novel risk factors as predictors of cardiovascular mortality. DESIGN, SETTING, AND PATIENTS: A total of 5808 community-dwelling persons aged 65 years or older living in 4 (...) communities in the United States participated in the Cardiovascular Health Study cohort. Participants were initially recruited from 1989 to June 1990; an additional 687 black participants were recruited in 1992-1993. The average length of follow-up in this longitudinal study was 8.6 years. MAIN OUTCOME MEASURES: Cardiovascular mortality among those with and without chronic kidney disease. Chronic kidney disease was defined as an estimated glomerular filtration rate of less than 60 mL/min per 1.73 m2

JAMA2005

715. Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review

Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review van der Pal H J, van Dalen E C, Kremer L C, Bakker P J, van Leeuwen F E CRD summary This review assessed the long-term risk (...) of cardiovascular disease after radiotherapy for childhood cancer. The authors concluded that cardiovascular mortality is increased after irradiation, but the risks of clinical cardiovascular events are unclear and further research is required. The well-described methodological limitations of the included studies weaken the strength of the evidence but support the need for further research. Authors' objectives To determine the long-term risk of cardiovascular disease (CVD) after radiotherapy for childhood

DARE.2005

716. EDTA chelation therapy for cardiovascular disease: a systematic review

EDTA chelation therapy for cardiovascular disease: a systematic review EDTA chelation therapy for cardiovascular disease: a systematic review EDTA chelation therapy for cardiovascular disease: a systematic review Seely D M, Wu P, Mills E J CRD summary This review assessed the treatment of cardiovascular disease with ethylene diamine tetraacetic acid chelation therapy. The authors concluded that there is no high-quality evidence to support any benefit from this treatment. These conclusions (...) are supported by the evidence presented. Authors' objectives To review the evidence on the effects of ethylene diamine tetraacetic acid (EDTA) chelation therapy in the treatment of cardiovascular disease (CVD). Searching MEDLINE, EMBASE, the Cochrane CENTRAL Register, AMED, AltHealthWatch, PreCINAHL, CINAHL, and the Nursing and Allied Health Collection were searched from inception to May 2005. The search strategy is available from the BMC Cardiovascular Disorders website. See Web Address at end of abstract

DARE.2005

717. Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: a systematic review

Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: a systematic review Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: a systematic review Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: a systematic review Innes K E, Bourguignon C, Taylor A G CRD summary The review determined (...) the efficacy of yoga on anthropometric and physiologic indices of cardiovascular disease risk and related end points. Based on a large number of diverse primary studies of limited quality, the authors are justified in concluding that further well-conducted research is necessary. Authors' objectives To determine the efficacy of yoga on anthropometric and physiologic indices (such as insulin resistance syndrome, IRS) of cardiovascular disease (CVD) risk and on related end points. Searching MEDLINE, IndMED

DARE.2005

718. Evaluating national guidelines for prevention of cardiovascular disease in primary care

Evaluating national guidelines for prevention of cardiovascular disease in primary care Evaluating national guidelines for prevention of cardiovascular disease in primary care Evaluating national guidelines for prevention of cardiovascular disease in primary care Marshall T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined national guidelines for the prevention of cardiovascular disease (CVD) in primary care. The guidelines for the USA, Canada, UK, New Zealand (NZ) and Australia were analysed. Each guideline identified three principal drug intervention areas. These were the lowering of blood pressure with antihypertensive drugs, aspirin, and the lowering of cholesterol with drugs. Type of intervention

NHS Economic Evaluation Database.2005

719. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project

Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project Coronary calcium independently predicts incident premature coronary heart disease over (...) for ethic minorities as well. Prospective clinical trials with accurate cost measurements are also necessary to achieve more robust cost-effectiveness results. Source of funding None stated. Bibliographic details Taylor A J, Bindeman J, Feuerstein I, Cao F, Brazaitis M, O'Malley P G. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project. Journal

NHS Economic Evaluation Database.2005

720. Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial.

Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. 15811982 2005 04 06 2005 04 11 2016 10 17 1538-3598 293 13 2005 Apr 06 JAMA JAMA Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. 1626-34 Observational studies have shown that psychosocial factors are associated with increased risk (...) for cardiovascular morbidity and mortality, but the effects of behavioral interventions on psychosocial and medical end points remain uncertain. To determine the effect of 2 behavioral programs, aerobic exercise training and stress management training, with routine medical care on psychosocial functioning and markers of cardiovascular risk. Randomized controlled trial of 134 patients (92 male and 42 female; aged 40-84 years) with stable ischemic heart disease (IHD) and exercise-induced myocardial ischemia

JAMA2005